2. Immunology/Inflammation
  3. Glycoprotein VI Interleukin Related
  4. SAR444200

SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.

For research use only. We do not sell to patients.

SAR444200

SAR444200 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

SAR444200 Related Antibodies

Top Publications Citing Use of Products

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3+ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma[1][2].

Species Reactivity

Human
IC50 & Target[1]

IL-6

 

IL-2

 

In Vitro

SAR444200 binds to human and cynomolgus monkey TCRαβ with single-digit nanomolar affinity, human and cynomolgus monkey GPC3 with sub-nanomolar affinity, and human and cynomolgus monkey albumin with single-digit nanomolar affinity, with lower affinity to mouse orthologues and no cross-reactivity to mouse TCR[1].
SAR444200 (24 h) binds to membrane-bound human GPC3 with sub-nanomolar affinity and membrane-bound cynomolgus monkey GPC3 with low sub-nanomolar affinity[1].
SAR444200 (60 h) potently induces T-cell-dependent cellular cytotoxicity of GPC3+ human HepG2, NCI-H661, and HuH-7 cells with sub-nanomolar EC50 values, shows cross-reactive cytotoxicity against cynomolgus monkey GPC3-expressing HEK293 cells, and exhibits no activity against GPC3-low NCI-H23 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SAR444200 Related Antibodies
In Vivo

SAR444200 (0.2-2.0 mg/kg; intravenous injection; once every 3 days; 5 doses total) induces tumor regression in HepG2 hepatocellular carcinoma humanized NOG mice and HuH-7 hepatocellular carcinoma humanized NOG mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOG (NOD.Cg-PrkdcscidIL2tm1Sug/Jital) (10-week-old female, humanized with HepG2 cells and human T cells)[1]
Dosage: 2.0 mg/kg; 0.7 mg/kg; 0.2 mg/kg
Administration: i.v.; every third day; 5 doses
Result: Showed significant antitumor activity with 100% tumor inhibition at day 33, and induced 1 complete regression and 5 partial regressions at 2.0 mg/kg.
Showed significant antitumor activity with 100% tumor inhibition at day 33, and induced 1 complete regression and 3 partial regressions at 0.7 mg/kg.
Showed non‑significant antitumor activity with 29% tumor inhibition at day 33 at 0.2 mg/kg.
Animal Model: NOG (NOD.Cg-PrkdcscidIL2tm1Sug/Jital) (10-week-old female, humanized with HuH-7 cells and human T cells)[1]
Dosage: 2.0 mg/kg; 0.7 mg/kg; 0.2 mg/kg
Administration: i.v.; every third day; 5 doses
Result: Achieved significant antitumor activity with 100% tumor inhibition at day 35 and induced 3 complete regressions and 1 partial regression at 0.7 mg/kg.
Displayed significant antitumor activity with 67% tumor inhibition at day 35 and induced 1 complete regression and 3 partial regressions at 2.0 mg/kg.
Showed non-significant antitumor activity with 54% tumor inhibition at day 35 at 0.2 mg/kg.
Gene ID

2719  [NCBI]

Accession
Target

TCRαβ & GPC3
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

SAR444200 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SAR444200SAR 444200SAR-444200Glycoprotein VIInterleukin RelatedGPVIILHepG2hepatocellular carcinomaGlypican-3interferon gammaT cellsTCRαβinterleukin-6human cancer xenograftstumor cellsGPC3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SAR444200
Cat. No.:
HY-P992457
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.